Cancer Family
Digestive System Neoplasm
CI-CAN-00000012Explore in graph →
Non-malignant4,732 active trials43 approved drugs557 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000012Explore in graph →
Clinical trials
22,051 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07229625 | A Phase III Study of SHR-8068 in Combination With Adebrelimab and Platinum-Containing Chemotherapy Versus Durvalumab in Combination With Platinum-Containing Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer (BTC) | recruiting | Phase 3 | 604 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Jan 28, 2026 | clinicaltrials |
| NCT07372300 | Modulated Electro-Hyperthermia in Combination With Multimodal Therapy for Locally Advanced Rectal Cancer(mEHT) | recruiting | Phase 3 | 126 | Shih-Kai HungOTHER |
| 1 |
| Jan 28, 2026 |
| clinicaltrials |
| NCT07366528 | Adjuvant Oxaliplatin Plus S-1 Versus Docetaxel Plus S-1 for Stage III Gastric Cancer | recruiting | Phase 3 | 387 | Ruijin HospitalOTHER | 1 | Jan 26, 2026 | clinicaltrials |
| NCT05855200 | Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer | recruiting | Phase 3 | 892 | GlaxoSmithKlineINDUSTRY | 28 | Jan 23, 2026 | clinicaltrials |
| NCT07361003 | A Phase Ib/III Study of Suvemcitug Plus FTD/TPI in Participants With Refractory Metastatic Colorectal Cancer | recruiting | Phase 3 | 464 | Jiangsu Simcere Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 22, 2026 | clinicaltrials |
| NCT04821843 | Neoadjuvant Treatment Modalities in Esophageal Cancer | recruiting | Phase 3 | 2,000 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT04342910 | Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC | recruiting | Phase 3 | 550 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jan 20, 2026 | clinicaltrials |
| NCT03875781 | Non Inferiority Study of Preoperative Chemotherapy Without Pelvic Irradiation for Rectal Cancer(NORAD01) | recruiting | Phase 3 | 540 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jan 15, 2026 | clinicaltrials |
| NCT06312982 | A Series of Neoadjuvant Chemoradiotherapy Combined With Immunotherapy for Locally Advanced Rectal Cancer | recruiting | Phase 2 / Phase 3 | 375 | Beijing Friendship HospitalOTHER | 1 | Jan 13, 2026 | clinicaltrials |
| NCT04095299 | Standard Dose Versus High Dose of Radiotherapy in Rectal Preservation With Chemo-radiotherapy in Rectal Cancer Patients(WW3) | recruiting | Phase 3 | 162 | Vejle HospitalOTHER | 1 | Jan 8, 2026 | clinicaltrials |
| NCT06676449 | TDLN-sparing RT Plus Immunotherapy and Chemotherapy in Locally Advanced ESCC | recruiting | Phase 3 | 432 | Fudan UniversityOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT04353375 | HMPL-453 Tartrate in Advanced Intrahepatic Cholangiocarcinoma | recruiting | Phase 2 / Phase 3 | 235 | HutchmedINDUSTRY | 1 | Dec 31, 2025 | clinicaltrials |
| NCT07309289 | NALIRIFOX Plus Targeted Therapy Versus FOLFOX Plus Targeted Therapy as First-line Treatment for Metastatic Colorectal Cancer | recruiting | Phase 3 | 144 | Shanghai Zhongshan HospitalOTHER | 1 | Dec 30, 2025 | clinicaltrials |
| NCT06791512 | mFOLFOX6 + Bevacizumab + PD-1 Monoclonal Antibody Vs. mFOLFOX6 in Locally Advanced pMMR/MSS CRC(BASKETⅢ) | recruiting | Phase 3 | 166 | Jun HuangOTHER | 1 | Dec 24, 2025 | clinicaltrials |
| NCT05317819 | Study of ADI-PEG 20 Versus Placebo in Subjects With High Arginine Level and Unresectable Hepatocellular Carcinoma | recruiting | Phase 3 | 300 | Polaris GroupINDUSTRY | 2 | Dec 18, 2025 | clinicaltrials |
| NCT06686576 | A Study of Neoadjuvant QL1706 in Participants With Untreated dMMR/MSI-H Resectable Colon Cancer | recruiting | Phase 3 | 363 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Dec 18, 2025 | clinicaltrials |
| NCT07029269 | Feasibility of Enhanced Recovery After Surgery Without Prophylactic Abdominal Drainage Tubes After Laparoscopic Distal Gastrectomy For Gastric Cancer | recruiting | Phase 3 | 454 | Zuoyi JiaoOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT07285850 | The Efficacy of Sequential Treatment With Bevacizumab Combined With Atezolizumab in Advanced Liver Cancer With MASLD(ABATE-MASLD) | recruiting | Phase 2 / Phase 3 | 20 | Eastern Hepatobiliary Surgery HospitalOTHER | 1 | Dec 16, 2025 | clinicaltrials |
| NCT05008809 | Post-resection/Ablation Chemotherapy in Patients With Metastatic Colorectal Cancer (FIRE-9 - PORT / AIO-KRK-0418) | recruiting | Phase 3 | 507 | Dominik Paul ModestOTHER | 1 | Dec 12, 2025 | clinicaltrials |
| NCT07272772 | Colon Cancer Diagnosis With FAPI-PET Imaging | recruiting | Phase 2 / Phase 3 | 100 | Turku University HospitalOTHER_GOV | 1 | Dec 9, 2025 | clinicaltrials |
| NCT06733038 | FOLFOXIRI Plus Bevacizumab With or Without Atezolizumab as 1st Line Treatment of pMMR and IS IC-High Metastatic Colorectal Cancer Patients.(AtezoTRIBE2) | recruiting | Phase 3 | 238 | Gruppo Oncologico del Nord-OvestOTHER | 1 | Dec 8, 2025 | clinicaltrials |
| NCT06172205 | Infusional FOLFOX Plus Camrelizumab and Apatinib vs HAIC-FOLFOX Plus Camrelizumab and Apatinib for Advanced HCC | recruiting | Phase 3 | 262 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Dec 3, 2025 | clinicaltrials |
| NCT05786716 | DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations(DETERMINE) | recruiting | Phase 2 / Phase 3 | 30 | Cancer Research UKOTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT05768178 | DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.(DETERMINE) | recruiting | Phase 2 / Phase 3 | 30 | Cancer Research UKOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT05770102 | DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition(DETERMINE) | recruiting | Phase 2 / Phase 3 | 30 | Cancer Research UKOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT06988475 | DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations(DETERMINE) | recruiting | Phase 2 / Phase 3 | 30 | Cancer Research UKOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT06940947 | Endoscopic Therapy Or Surgery for Early Colon Cancer(ETHOS) | recruiting | Phase 3 | 434 | Norwegian Department of Health and Social AffairsOTHER_GOV | 1 | Nov 20, 2025 | clinicaltrials |
| NCT07103668 | A Phase III Randomized Study in CLDN18.2-positive Unresectable Locally Advanced Gastric Cancer Patients | recruiting | Phase 3 | 150 | Suzhou Immunofoco Biotechnology Co., LtdINDUSTRY | 1 | Oct 23, 2025 | clinicaltrials |
| NCT02000089 | The Cancer of the Pancreas Screening-5 CAPS5)Study(CAPS5) | recruiting | Phase 3 | 9,000 | Johns Hopkins UniversityOTHER | 1 | Oct 9, 2025 | clinicaltrials |
| NCT06644937 | Single-arm Clinical Trial of TACE in Combination With Icaritin as Adjuvant Therapy After Surgery in Patients With Hepatocellular Carcinoma at High Risk of Recurrence | recruiting | Phase 2 / Phase 3 | 30 | Zhujiang HospitalOTHER | 1 | Sep 23, 2025 | clinicaltrials |
| NCT07079228 | A Study to Compare QLS31905 and Chemotherapy With Placebo and Chemotherapy in Participants With Pancreatic Cancer | recruiting | Phase 3 | 602 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 23, 2025 | clinicaltrials |
| NCT07186621 | Adjuvant Radiotherapy of Sintilimab Versus TACE for HCC | recruiting | Phase 3 | 286 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Sep 22, 2025 | clinicaltrials |
| NCT07155525 | Tissue Adhesive Glue Modified Cyanoacrylate (Glubran® 2) in Soft Pancreas(NBCA-MS) | recruiting | Phase 3 | 194 | Minia UniversityOTHER | 1 | Sep 18, 2025 | clinicaltrials |
| NCT06207981 | Phase III Study Evaluating Induction Chemotherapy Followed by Chemoradiotherapy Compared to Standard Chemoradiotherapy for Locally Advanced SCCA(KANALRAD) | recruiting | Phase 3 | 310 | Federation Francophone de Cancerologie DigestiveOTHER | 2 | Sep 2, 2025 | clinicaltrials |
| NCT06490536 | The Sagittarius Trial | recruiting | Phase 3 | 700 | IFOM ETS - The AIRC Institute of Molecular OncologyOTHER | 3 | Aug 29, 2025 | clinicaltrials |
| NCT07018661 | [18F]F-FAPI PET/CT and Laparoscopy in Staging Advanced Gastric Cancer(PLASTIC-3) | recruiting | Phase 2 / Phase 3 | 250 | Leiden University Medical CenterOTHER | 1 | Aug 27, 2025 | clinicaltrials |
| NCT07066098 | A Multicenter Study of IBI343 Monotherapy Versus Placebo in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, Pancreatic Cancer(G-HOPE-002) | recruiting | Phase 3 | 201 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Aug 15, 2025 | clinicaltrials |
| NCT06095141 | Cisplatin to Patients With Pancreatic Cancer and Homologous Recombination Deficiency(PTCA199-6) | recruiting | Phase 2 / Phase 3 | 30 | Fudan UniversityOTHER | 1 | Aug 7, 2025 | clinicaltrials |
| NCT06250972 | Radiotherapy to Patients With CA19-9-elevated Advanced Pancreatic Cancer(PTCA199-11) | recruiting | Phase 3 | 210 | Fudan UniversityOTHER | 1 | Aug 7, 2025 | clinicaltrials |
| NCT06958419 | Node-Sparing Short-Course Radiotherapy Plus Chemotherapy, Bevacizumab and PD-1 Inhibitor in Metastatic pMMR/MSS Colorectal Cancer (MODIFI-CRC) | recruiting | Phase 2 / Phase 3 | 286 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | Aug 7, 2025 | clinicaltrials |
| NCT06841172 | Continuation of First-line Therapy With Radiotherapy Versus Early Switch to Second-line Therapy in Oligoprogressive HCC | recruiting | Phase 3 | 132 | Shandong Cancer Hospital and InstituteOTHER | 1 | Aug 1, 2025 | clinicaltrials |
| NCT07098598 | Pancreatic Cancer Diagnosis With FAPI-PET Imaging | recruiting | Phase 2 / Phase 3 | 100 | Turku University HospitalOTHER_GOV | 1 | Aug 1, 2025 | clinicaltrials |
| NCT06441565 | Fruquintinib With or Without HAI-FOLFOX for Refractory Colorectal Cancer | recruiting | Phase 2 / Phase 3 | 84 | Sun Yat-sen UniversityOTHER | 1 | Jul 30, 2025 | clinicaltrials |
| NCT06793917 | Tislelizumab Plus FOLFOX Versus POF in the Treatment of Locally Advanced: a Multicenter, Open-label, Randomized Phase III Studyunresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma | recruiting | Phase 3 | 269 | Fujian Cancer HospitalOTHER_GOV | 1 | Jul 20, 2025 | clinicaltrials |
| NCT07070622 | Planed Organ Preservation for Low Rectal Cancer After Neoadjuvant Chemotherapy (OPLAR)(OPLAR) | recruiting | Phase 3 | 186 | West China HospitalOTHER | 1 | Jul 17, 2025 | clinicaltrials |
| NCT07062263 | Trastuzumab Plus Chemotherapy vs Chemotherapy Alone in First-line HER2 Positive Advanced Biliary Tract Cancer Patients(TAB-2) | recruiting | Phase 3 | 220 | Tata Memorial CentreOTHER | 1 | Jul 14, 2025 | clinicaltrials |
| NCT06949033 | Neoadjuvant Cadonilimab Combined With Perioperative Oxaliplatin Plus S1 for Diffuse or Mixed Type of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma | recruiting | Phase 3 | 668 | Zuoyi JiaoOTHER | 1 | Jul 10, 2025 | clinicaltrials |
| NCT02885753 | Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver(OSCAR) | recruiting | Phase 3 | 348 | Federation Francophone de Cancerologie DigestiveOTHER | 2 | Jul 9, 2025 | clinicaltrials |
| NCT07020247 | Personalized Long-course Radiotherapy Plus Chemotherapy With or Without Immunotherapy for LARC: PALACE Study | recruiting | Phase 3 | 184 | West China HospitalOTHER | 1 | Jun 13, 2025 | clinicaltrials |
| NCT04861558 | Efficacy of Hyperthermic Intraperitoneal Chemotherapy(EFFIPEC) | recruiting | Phase 3 | 213 | Uppsala UniversityOTHER | 2 | May 30, 2025 | clinicaltrials |
Data updated 22 days agoSource updated Jan 28, 2026source: clinicaltrials